Anthony (Tony) White

Senior Partner

Email: tony.white@transcrip-partners.com

Tony White, B Tech, is a microbiologist with over 35 years' experience in the field of antibacterials. He originally joined Beecham Pharmaceuticals Research in 1976, where he worked on the microbiology of amoxicillin/clavulanic acid and developed in vitro kinetic models to support this and other antibacterials marketed by Beecham. From 1986 he was Project Director responsible for development of new antibacterials as well as amoxicillin/clavulanic acid and was involved in development of the amoxicillin/clavulanic acid twice-daily dosage regimen. From 1995, he was a member of the central marketing team, responsible for antibacterial differentiation where he managed the pioneering Alexander Project global surveillance study. This, along with the emerging science of pharmacokinetics/pharmacodynamics, led to the development of strategies to optimise amoxicillin/clavulanic acid using high-dose regimens. Until 2005, Tony was in charge of GlaxoSmithKline's antibacterial scientific communication and publication activities. Tony has been responsible for over 30 scientific symposia, and a number of global advisory boards, including the Consensus meetings on the appropriate prescribing of antibacterials for community infections.

Tony White has authored many scientific articles, including those covering specific antibacterials, pharmacokinetics/pharmacodynamics, resistance surveillance programmes and the pharmaceutical company response to antibiotic policies and has presented widely on these topics. He has been a member of European Union working parties and World Health Organization groups developing strategy plans to contain antibacterial resistance and represented the European pharmaceutical industry (EFPIA) as co-chair of the antibiotic resistance working group. He is currently an independent consultant on antibacterial development and communications and member of the British Society for Antimicrobial Chemotherapy (BSAC) surveillance working party and a former member of BSAC Council and the BSAC Urgent Need Working Party for regenerating antibacterial drug discovery development.